MedPath

Curevo Vaccine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Curevo Vaccine, a clinical-stage biotechnology company, will present updated data from its 876-patient trial of amezosvatein, a shingles vaccine, at the 43rd Annual J.P. Morgan Healthcare Conference.

Curevo Vaccine, a privately held clinical-stage biotechnology company focused on developing safe and effective vaccines to reduce the burden of infectious diseases, has announced its selection to present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation, led by CEO George Simeon, will cover updated data from Curevo's 876-patient head-to-head trial of amezosvatein, a non-mRNA adjuvanted subunit vaccine for shingles, compared to Shingrix®.
The presentation is scheduled for Wednesday, January 15th, at 5:00pm Pacific Standard Time in the Golden Gate room on the 32nd floor. Curevo's lead product, amezosvatein, aims to address the current challenges in the shingles vaccine market, including accessibility issues and vaccine hesitancy due to tolerability concerns. The company is also developing a non-live, non-mRNA adjuvanted subunit chickenpox vaccine to improve immunization rates among immunocompromised children.
Shingrix® is a registered trademark of GlaxoSmithKline, PLC.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Curevo's Amezosvatein Shows Sustained Immunogenicity and Improved Tolerability in Phase 2 Shingles Vaccine Trial

Curevo's amezosvatein maintained non-inferior anti-gE antibody levels compared to Shingrix one year after the second dose in adults aged 50-69.
The Phase 2 trial (NCT05304351) demonstrated that amezosvatein had a statistically significant improvement in Grade 2 and 3 reactogenicity versus Shingrix.

Azafaros to Present at J.P. Morgan's 43rd Annual Healthcare Conference

Azafaros, a company specializing in treatments for rare lysosomal storage disorders, will present at J.P. Morgan's 43rd Annual Healthcare Conference. The presentation will focus on nizubaglustat, their lead product, which has shown promising results in Phase 2 studies for treating GM1/GM2 gangliosidoses and Niemann Pick type C.

Ocular Therapeutix to Present AXPAXLI Update at J.P. Morgan Healthcare Conference

Ocular Therapeutix will present its 2025 strategic outlook at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.
An update on the enrollment status of the SOL-R trial, evaluating AXPAXLI for wet AMD, will be provided during the presentation.

Areteia Therapeutics Advances Oral Dexpramipexole for Eosinophilic Asthma in Phase III Trials

Areteia Therapeutics is progressing dexpramipexole, a novel oral therapy, into Phase III clinical trials for severe eosinophilic asthma.
Dexpramipexole aims to reduce eosinophil levels by inhibiting their maturation in the bone marrow, offering a potential alternative to injectable biologics.

Summit Therapeutics Advances Ivonescimab Program with Pfizer Collaboration and Phase III Trial Progress in NSCLC

Summit Therapeutics collaborates with Pfizer to evaluate ivonescimab with Pfizer's ADCs across solid tumors, aiming to improve therapeutic combinations.
Enrollment is complete for the Phase III HARMONi trial in EGFR-mutated NSCLC, with top-line data expected mid-2025, and FDA Fast Track designation granted.

Biogen and Stoke Therapeutics Collaborate to Advance Zorevunersen for Dravet Syndrome

Biogen and Stoke Therapeutics will collaborate to develop and commercialize zorevunersen for Dravet syndrome outside the U.S., Canada, and Mexico.
Stoke's Phase 3 EMPEROR study of zorevunersen, expected to begin in mid-2025, aims to reduce seizure frequency and improve cognition and behavior in children with Dravet syndrome.

OS Therapies to Present Phase 2b Osteosarcoma Trial Data at JP Morgan Healthcare Conference, Eyes $150M Priority Review Voucher

OS Therapies (NYSE-A: OSTX) will present updates from their Phase 2b trial of OST-HER2 for recurrent osteosarcoma at the upcoming JP Morgan Healthcare Conference. The company anticipates potential FDA approval in 2025, which could earn them a Priority Review Voucher worth approximately $150 million, enabling expansion into other HER2-positive cancers.

ZyVersa Therapeutics to Present Kidney Disease Drug VAR 200 at JPM Healthcare Conference 2025

ZyVersa Therapeutics' CEO, Stephen C. Glover, will attend the JPM Healthcare Conference in January 2025 to discuss the company's pipeline.
VAR 200, a Cholesterol Efflux Mediator, is set to begin Phase 2a clinical trials for diabetic kidney disease in Q1 2025.

Curevo's Amezosvatein Shows Zero Shingles Cases in Phase 2 Trial

Curevo's amezosvatein vaccine demonstrated zero confirmed cases of shingles in a Phase 2 trial after 18.8 months of follow-up, contrasting with an expected 10 cases without vaccination.
The Phase 2 trial (NCT05304351) compared amezosvatein head-to-head against Shingrix in 876 participants aged 50 and older, showing comparable safety profiles between the two vaccines.

Curevo's Amezosvatein Shows Promise in Phase 2 Trial with Improved Tolerability for Shingles Vaccine

Curevo Vaccine's amezosvatein demonstrated non-inferiority to Shingrix in a Phase 2 trial, meeting all primary endpoints for immunogenicity.
The trial, involving 876 participants, showed amezosvatein had a 100% vaccine response rate compared to Shingrix's 97.9%.

Reference News

[1]
Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference
finance.yahoo.com · Jan 8, 2025

Curevo Vaccine, a Seattle-based biotech company, will present at the 43rd Annual J.P. Morgan Healthcare Conference. CEO ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy